The Federal Government of Nigeria is moving to integrate GenScan AI into the national healthcare infrastructure following its selection as the winner of the 2026 Nigeria LNG (NLNG) Prize for Science and Innovation. Developed by researcher Mary-Brenda Akoda, the technology offers a method to reduce magnetic resonance imaging (MRI) acquisition time by up to 90 percent while maintaining diagnostic integrity on existing hospital hardware.
Dr. Tunji Alausa, the Minister of Education, announced the government’s intent to facilitate clinical pilot programs across Nigerian teaching hospitals and Federal Medical Centres during a presentation in Abuja on Monday. The initiative seeks to bridge the gap between laboratory research and clinical application, addressing the persistent issue of diagnostic delays in the country’s public health sector.
The innovation emerged from Akoda’s postgraduate research at Imperial College London, where it underwent rigorous technical validation. The system functions by processing a fraction of the data typically required for a standard MRI, reconstructing full-quality diagnostic images without the need for new, multi-million dollar scanners. Technical assessments indicate that the reconstructed images achieve a 99.7 percent similarity to conventional scans.
A blinded evaluation conducted at Buckinghamshire NHS Hospital in the United Kingdom confirmed the clinical viability of the approach. A consultant radiologist assessed the GenScan AI output as diagnostically equivalent to standard imaging in every case reviewed. This validation is critical for the technology’s adoption in environments where high-end equipment is often scarce or overextended.
The economic implications for healthcare providers are significant, as conventional MRI scanners typically cost between $1.5 million and $3.5 million. By extending the utility of existing machines, the software model allows institutions to increase patient throughput without capital-intensive hardware procurement. Akoda noted that the technology also mitigates risks associated with patient movement, which often necessitates repeat scans or sedation for vulnerable populations.
The 2026 NLNG prize attracted 237 entries, highlighting a competitive landscape for digital health solutions in Nigeria. Prof. Bart Nnaji, Chairman of the Advisory Board for the prize, emphasized that the award recognizes work with tangible societal impact rather than purely academic achievement. The selection process prioritized innovations capable of addressing immediate infrastructure constraints within the national medical system.
Dr. Sophia Horsfall, General Manager of External Relations and Sustainable Development at NLNG, noted that the focus for this year’s cycle was on artificial intelligence and digital technologies. The organization aims to foster research that provides practical, scalable solutions to local challenges. The integration of GenScan AI represents a strategic effort to align advanced computational research with the operational realities of Nigerian hospitals.
The significance of this development lies in the potential to alleviate the strain on diagnostic services where waiting times can extend for hours. By reducing a 60-minute scan to approximately six minutes, the technology directly addresses the bottleneck in patient care workflows. This efficiency gain is particularly relevant for stroke management and other time-sensitive medical conditions where rapid imaging is essential for clinical decision-making.
The broader adoption of this AI model could serve as a case study for the deployment of software-defined medical imaging in resource-constrained environments. Future efforts will focus on expanding the platform’s capabilities beyond MRI to include CT scans, chest X-rays, and angiography. The success of the upcoming clinical pilots will determine the scalability of the model across the federal health network.
Stakeholders in the medical technology sector are now monitoring the transition from the research phase to clinical implementation. The success of this pilot will depend on the collaboration between government health agencies and private diagnostic centers. If the technology performs as expected in local settings, it could establish a new benchmark for diagnostic efficiency in emerging markets.
